JHS — JHS Svendgaard Laboratories Balance Sheet
0.000.00%
- IN₹917.67m
- IN₹823.24m
- IN₹919.97m
- 32
- 50
- 26
- 24
Annual balance sheet for JHS Svendgaard Laboratories, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | R2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 232 | 89 | 377 | 50.5 | 183 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 712 | 453 | 311 | 156 | 152 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 1,210 | 790 | 848 | 437 | 538 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 710 | 773 | 728 | 878 | 870 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 2,280 | 2,220 | 2,282 | 1,971 | 2,012 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 231 | 189 | 367 | 233 | 247 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 393 | 361 | 544 | 272 | 284 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 1,887 | 1,859 | 1,738 | 1,699 | 1,727 |
| Total Liabilities & Shareholders' Equity | 2,280 | 2,220 | 2,282 | 1,971 | 2,012 |
| Total Common Shares Outstanding |